Belumosudil
Small molecule
Also known as KD025
Evidence outlook
Approved: Chronic Graft-versus-Host Disease, Graft-versus-Host Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
Also approved (3)
- Rezurock is indicated for the treatment of adults and paediatric patients (12 years and older with a body weight of at least 40 kg) with chronic graft-versus-host disease (cGVHD) when other treatment options provide limited clinical benefit, are not suitable, or have been exhausted.
- Treatment of chronic graft-versus-host disease after hematopoietic stem cell transplantation (for use when steroid drugs are not sufficiently effective)
- REZUROCK is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy. Efficacy in patients with chronic GVHD was based on objective response rate and duration of response in a single-arm study (see 14 CLINICAL TRIALS).
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ROCKnrol-1 NCT06143891 · Chronic Graft-versus-Host Disease Registry: NCT06143891 | 3 | Event-Free Survival (EFS) (Until the end of the study (up to 2.5 years since first patient in).) 2028-09-29 | In progress: results expected 29 Sept 2028 | not yet graded | link ↗ |
View 1 more trial
NCT03640481 NCT03640481 · Chronic Graft-versus-Host Disease Every participant received belumosudil: patients were randomized only between two doses, with no placebo or standard-therapy comparison group and no blinding. Response was judged by investigators who knew the treatment, so the response rates cannot show how much benefit is due to the drug. Registry: NCT03640481 | 2 | Overall Response Rate (ORR) (From the date of randomization to the date of first documentation of progression or death due to any cause or data cut-off, whichever occurred first (maximum duration: up to 40.5 months for adult arms and 27.6 months for adolescent arms)) 2023-12-11 | Overall Response Rate (ORR) (From the date of randomization to the date of first documentation of progression or death due to any cause or data cut-off, whichever occurred first (maximum duration: up to 40.5 months for adult arms and 27.6 months for adolescent arms)): Adult Arm A: Belumosudil 200 mg QD 74 Percentage of participants | Adult Arm B: Belumosudil 200 mg BID 76 Percentage of participants | Adolescent Arm A: Belumosudil 200 mg QD 50 Percentage of participants | Adolescent Arm B: Belumosudil 200 mg BID 100 Percentage of participants | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (18)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (2)
What this study did
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Competitive landscape
Other Rho-associated kinase (ROCK, pan) drugs
ROC-101. Compare all 2 Rho-associated kinase (ROCK, pan) drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Chronic Graft-versus-Host Disease: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Belumosudil: this drug | Approved | Small molecule | Rho-associated kinase (ROCK, pan) | Weak signal | NCT03640481: Overall Response Rate (ORR) (From the date of randomization to the date of first documentation of progression or death due to any cause or data cut-off, whichever occurred first (maximum duration: up to 40.5 months for adult arms and 27.6 months for adolescent arms)): Adult Arm A: Belumosudil 200 mg QD 74 Percentage of participants | Adult Arm B: Belumosudil 200 mg BID 76 Percentage of participants | Adolescent Arm A: Belumosudil 200 mg QD 50 Percentage of participants | Adolescent Arm B: Belumosudil 200 mg BID 100 Percentage of participants | |
| Axatilimab | Approved | Monoclonal antibody | CSF-1R | Weak signal | Featured results are non-efficacy only in this race | |
| Ibrutinib | Approved | Small molecule | BTK | not yet graded | No reviewed efficacy summary in this indication | |
| Ruxolitinib (Jakafi) | Approved | Small molecule | JAK1/2 | Partial signal | NCT03112603: Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 Visit (Cycle 7 Day 1 (each cycle was comprised of 4 weeks)): Ruxolitinib 49.7 percentage of participants (95% CI 41.8 to 57.6) | Best Available Therapy 25.6 percentage of participants (95% CI 19.1 to 33) | |
| ROC-101 | Phase 2(overall) | Small molecule | Rho-associated kinase (ROCK, pan) | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(18 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Belumosudil to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.